MOH

ANALYST NOTE: MOLINA HEALTHCARE, INC. (MOH) DATE: 2026-06-13 CURRENT PRICE: $195.37

1. Structural Readiness

• State: Context-Only.
• Conservative Entry: Not applicable (Breakout has not fired).
• Aggressive/Pre-Breakout Entry: Not applicable (Setup is forming, not confirmed).
• Breakout Level: Not yet established.
• Current Price: $195.37.
• Extension: Not applicable (Price is not extending from a confirmed breakout).
• ATR Context: Current ATR is 3.9% (Productive). This sits within the historical "sweet spot" (4–6% is high, but 3.9% is productive and manageable for sizing), indicating volatility is present but not in the "extreme" (>8%) or "weak" (<2.5%) zones.

2. Thesis Layer

• Thesis Classification: Tactical / Setup-Led.
• Macro Thesis: There is no named secular thesis attached to this name as of 2026-06-13.
• Judgment Framework: The investment case must be judged strictly on the quality of the technical setup (the forming coil) and the immediate business fundamentals (guidance, margin trajectory, strategic shifts). Do not invent a macro narrative. The conviction stack relies on the alignment of management's strategic pivot (Medicaid/Medicare mix) with the structural price action.

3. The Business

Molina Healthcare, Inc. is a Fortune 500 company providing managed healthcare services primarily through Medicaid, Medicare, and state insurance marketplaces. As of the latest reporting period (March 31, 2026), the company served approximately 5.0 million members across 21 states.

Key Business Dynamics (as of April 23, 2026):

• Strategic Pivot: Management is executing a significant strategic shift to focus exclusively on dual-eligible members (those enrolled in both Medicaid and Medicare) and is exiting the standard Medicare Advantage (MAPD) product for 2027. This is driven by a determination that the MAPD product does not align with their long-term strategic focus.
• Enrollment Trajectory: The company is managing a contraction in enrollment to restore target margins.
• Medicaid: Expected to decline 6% in 2026 (revised from a previous 2% decline), settling at 4.5 million members by year-end. This is attributed to general market contraction and the impact of the OBBBA law (signed July 2025), which introduces work requirements and cost-sharing.
• Marketplace: Expected to decrease to ~250,000 members by year-end as part of a pricing strategy to restore margins.
• Medicare: Expected to decrease by ~12% to 230,000 members, including 80,000 MAPD members, due to the strategic exit.
• Financial Guidance:
• Earnings: Management reaffirmed full-year 2026 adjusted EPS guidance of at least $5.00.
• Revenue: Full-year 2026 premium revenue guidance remains at approximately $42 billion.
• Long-Term Targets: The company maintains a long-term premium revenue growth target of 11% to 13% and a net income growth target of 11% to 13%. Management expects to surpass the $50 billion premium revenue mark in 2027.
• Cost Structure: In Medicaid, the full-year Medical Cost Ratio (MCR) is expected to be 92.9%, reflecting 4% rate increases and a 5% medical cost trend.
• Growth Engines: Newly reported RFP successes and acquisitions in 2025 represent nearly $9 billion of incremental annual premium revenue.

4. Archetype and Conviction

• Archetype: Quality Compounder (with elements of a Margin Inflector).
• *Fit:* The company is transitioning from a volume-driven model (broad MAPD/Marketplace) to a higher-quality, dual-eligible focused model. The guidance for $5.00+ EPS and $42B revenue, despite enrollment declines, suggests a successful margin inflection strategy where revenue per member is increasing faster than the loss of volume. The "Quality Compounder" label fits the disciplined execution of exiting lower-margin segments to protect long-term franchise value.
• Valuation Context:
• Forward consensus EPS for FY1 (2026) is $5.1365.
• Forward consensus EPS for FY2 (2027) is $9.38952.
• *Note:* The significant jump in FY2 consensus implies the market expects the strategic exit of MAPD and the realization of the $50B revenue target to drive substantial earnings expansion in 2027.
• Conviction Stack:
• Thesis Strength: Moderate (Tactical, no macro tailwind, but strong internal strategic clarity).
• Evidence Quality: High (Direct management guidance on EPS, Revenue, and specific enrollment shifts).
• Structural Quality: Moderate (ATR of 3.9% is productive; setup is "Forming," not "Confirmed").
• Rerating Potential: High, contingent on the successful execution of the 2027 revenue target and the stabilization of the dual-eligible franchise.

5. Invalidations, Strengths, and Gaps

• What Would Invalidate:
• A significant deviation from the $5.00 EPS guidance or the $42B revenue guidance in subsequent quarters.
• Failure to execute the 2027 exit of the MAPD product or a reversal in the dual-eligible strategy.
• What Would Strengthen:
• A confirmed breakout above the current resistance (firing the coil).
• Confirmation that the "run rate" of the Florida Kids program ($6B) is fully realized and contributing to the 2027 targets.
• Evidence that the MCR remains stable or improves despite the 5% medical cost trend.
• Gaps in Evidence:
• 2027 Specifics: While 2027 targets are mentioned ($50B revenue), the specific EPS guidance for 2027 is not explicitly stated in the provided transcript excerpts, only the consensus estimate.
• Regulatory Impact: The specific financial impact of the OBBBA law (work requirements/redeterminations) on the 15-20% enrollment reduction estimate is qualitative; the exact dollar impact is not quantified beyond the enrollment count.

PRIVATE ANALYST CALL

Judgment: Hold Confidence: medium Key risks: Enrollment decline accelerating beyond 6% in Medicaid due to OBBBA implementation; failure to execute MAPD exit by 2027; MCR rising above 92.9% due to medical cost trends. Sizing hint: Position size should be minimal or zero until a confirmed breakout occurs; current setup is forming, not active. Expected path: Management expects to navigate the enrollment contraction to restore margins, with revenue growth resuming in 2027 as the dual-eligible franchise scales and the $50B revenue target is approached. Expected horizon: 6 to 12 months for the setup to resolve (breakout or invalidation) and for the 2027 strategic shift to begin impacting financials.